Recent Progress in TSH Receptor Studies with a New Concept of "Autoimmune TSH Receptor Disease".

Mori, Toru; Akamizu, Takashi; Kosugi, Shinji; Sugawa, Hideo; Inoue, Daisuke; Okuda, Jyoji; Ueda, Yoshimichi

doi:10.1507/endocrj.41.1

Cited by 33 publications

(26 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the case numbers were too small for evaluation in their studies. Mori et al also reported the effectiveness of steroid treatment in terms of reduction in goiter size and remission in patients with Graves' disease [3]. In the patients whose TBII was negative at 24 months after pulse therapy, TBII values decreased faster than controls in our study (Fig.…”

Section: Discussionsupporting

confidence: 69%

“…However, glucocorticoids are seldom used for the treatment of Graves' disease, since there are other effective treatments with less adverse effects like antithyroid drugs (ATD). Therefore the effect of glucocorticoid therapy is poorly evaluated in Graves' disease [1][2][3]. Exceptionally large amounts of glucocorticoids are used for Graves' patients with severe ophthalmopathy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effect of High Dose Methylprednisolone Pulse Therapy Followed by Oral Prednisolone Administration on the Production of Anti-TSH Receptor Antibodies and Clinical Outcome in Graves' Disease

et al. 2005

View full text Add to dashboard Cite

Abstract. Little is known about the immunosuppressive effect of glucocorticoids on TSH receptor antibodies. We observed the long-term prognosis and serum TSH binding inhibitor immunoglobulin (TBII) levels in patients with Graves' ophthalmopathy who had received intravenous methylprednisolone pulse therapy (pulse therapy) followed by oral prednisolone administration in order to ascertain how long the immunosuppressive effect of glucocorticoids continued. This is the first report on the effect of pulse therapy on Graves' disease outcome. We observed 67 patients who were treated by antithyroid drugs (ATD) alone for 2 years after pulse therapy. TBII was evaluated before and 3, 6, 12, 18, and 24 months after pulse therapy. The mean TBII decreased significantly 3 months after pulse therapy (p<0.001), and was maintained until 24 months. There were 24 patients whose TBII was positive (>15%) at 24 months, in whom the mean TBII decreased significantly 3 to 6 months after pulse therapy (p<0.001), but increased again at 12 to 24 months (p<0.05). Thus, the immunosuppressive effect of glucocorticoids may be lost at 12 months after pulse therapy in these patients. The remission rate in the pulse therapy group was 40.98%, and that of the control patient group was 48.57%. There was no significant difference between the two. These results suggest that the immunosuppressive effect of pulse therapy was temporary, and that pulse therapy did not increase remission rate of Graves' disease.

show abstract

Section: Discussionsupporting

confidence: 69%

mentioning

confidence: 99%

Effect of High Dose Methylprednisolone Pulse Therapy Followed by Oral Prednisolone Administration on the Production of Anti-TSH Receptor Antibodies and Clinical Outcome in Graves' Disease

et al. 2005

View full text Add to dashboard Cite

show abstract

“…From the genetically intimate relationship between these two groups it has been suggested that they may belong to autoimmune TSH receptor disease [2]. The existence of TSBAb activity in F(ab')2 and Fab fragments has been reported previously [28].…”

Section: Latsmentioning

confidence: 78%

“…When TBII (with TSH receptor assay) and TSAb [CAMP production in porcine thyroid cells (PTC) assay] were determined, all LATS positive sera showed extremely high TSAb and TBII activities [12]. All available data indicate that TSH and TSAb may bind to the same site on the TSH receptor and that TSAb may be TRAb with a thyroid stimulating action [1,2]. Abnormally negative values in the TRAb (TBII) assay led to the discovery of bTSH binding antibody.…”

Section: Latsmentioning

confidence: 99%